2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

637. Myelodysplastic Syndromes: Clinical and Epidemiological

Program: Oral Abstract Session
Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Omics Technologies, Biological Processes, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Animal Model
PAPER

806 Heterogeneity of TP53 mutations in myeloid neoplasms: Simplifying complexity

Stephan Hutter, PhD, Sandra Huber, PhD2, Alessandro Baldi, PhD3, Anna Stengel, PhD4, Manja Meggendorfer, PhD5, Torsten Haferlach, MD, PhD6, Gregor Hoermann, MD7
1 MLL Munich Leukemia Laboratory, Munich, Germany
2 MLL Munich Leukemia Laboratory, Munich, Germany
3 MLL Munich Leukemia Laboratory, Munich, Germany
4 MLL Munich Leukemia Laboratory, Munich, Germany
5 MLL Munich Leukemia Laboratory, Munich, Germany
6 MLL Munich Leukemia Laboratory, Munich, Germany
7 MLL Munich Leukemia Laboratory, Munich, Germany

Background:

TP53 mutations (mut) frequently occur in myeloid neoplasms (MN) like myelodysplastic neoplasms (MDS) or acute myeloid leukemia (AML), are associated with adverse prognosis and have been suggested as entity-defining. Disease progression and genomic instability in TP53-mut patients is amongst others impacted by the allelic state, specifically bi-allelic inactivation, and variant allele fraction (VAF). Thus, current classification systems differ regarding TP53-mut as entity-definition in terms of the allelic state (either multi-hit or bi-allelic, i.e. inactivation of a second allele via second TP53-mut, del(17p) or copy-neutral loss of heterozygosity (CN-LOH)) and VAF cut-off. In addition, a multi-mutated state of TP53 can also occur in a multi-clonal background, i.e. mono-allelic TP53-mut in different (sub-)clones. Addressing these aspects will be crucial for harmonizing disease classifications.

Aim:

Evaluate the frequency and relevance of the different types of TP53-mut across AML and MDS and address related technical challenges to simplify currently discussed entity-defining inclusion criteria.

Methods:

We retrospectively evaluated peripheral blood or bone marrow samples of 3,010 TP53-mut patients diagnosed as MDS (n=1,509) or AML (n=1,501). TP53-mut were analyzed by either panel or whole genome sequencing (WGS). Status of del(17p) was established through sequencing (panels with copy-number spike-in or WGS), FISH, and/or chromosomal banding. CN-LOH status was assessed by sequencing (MDS: n=438; AML: n=151). Configuration (cis or trans) of TP53-mut pairs ≤180bp apart was established by analyzing fragment cooccurrence in high-coverage (>1,500x) BAM files (MDS: n=62; AML: n=67).

Results:

Most TP53-mut cases had only one TP53-mut (MDS: 75.6%, AML: 78.2%); an accompanying del(17p) was more frequent in AML (37.0% vs. 17.7% in MDS), while accompanying CN-LOH was more common in MDS (23.3% vs. 9.4% in AML). Occurrences of del(17p) or CN-LOH in conjunction with multiple TP53-mut were only rarely observed (<5%). Taken together, 66.4% of TP53-mut MDS and 68.1% of AML cases showed multiple TP53 aberrations. TP53-mut VAF ≥10% were observed in 74.1% of MDS and 90.9% of AML cases. VAF >50% is often used as proxy for determining bi-allelic state. Indeed, there was a strong association of TP53-mut >50% VAF with the presence of CN-LOH (72.1% concordance in MDS; 90.3% in AML). Formally, multiple TP53-mut without del(17p) or CN-LOH (MDS: 21.8%, AML: 17.5%) can only be viewed as bi-allelic if the TP53-mut affect different alleles (trans configuration). We found that neighboring TP53-mut pairs in 100% of cases occurred exclusively in trans suggesting that cis configuration of multi-TP53-mut is extremely rare. To take into account the possibility of multi-clonal, mono-allelic TP53-mut, we used a VAFs sum of >50% to classify 37.8% of multi-TP53-mut MDS and 71.3% AML as unambiguously bi-allelic, while the remaining cases (a total of 13% of TP53-mut MDS and 5% AML) were considered probable bi-allelic. Overall survival (OS) analysis of cases with VAF ≥10% showed similarly poor survival for bi-allelic AML, bi-allelic MDS, and mono-allelic AML (median OS: 0.2, 0.8, and 0.6 years) in contrast to mono-allelic MDS (median OS: 4.3 years, p<0.001 in all comparisons) which was comparable to MDS with TP53-mut VAF <10% (median OS: 4.4 years). Subgroup analysis within bi-allelic MDS indicated a slightly worse OS of patients with del(17p)/CN-LOH compared to multi-mutated MDS (median OS: 0.4 vs. 1.2 years, p=0.04).

Conclusions:

The allelic state of TP53-mut can be confirmed or inferred from standard diagnostic data in the majority of TP53-mut MN: multi-hit is a feasible proxy for bi-allelic in cases with VAF ≥10%, specific analysis of CN-LOH is recommended, while phasing of multiple TP53-mut can be omitted. OS data support the concept of a common category of MN with bi-allelic TP53 inactivation (VAF ≥10%) while discriminating mono-allelic TP53 mutated MDS from AML. Whether the possibility of mimicking bi-allelic MDS in some patients by multiple mono-allelic TP53-mut in different (sub-)clones has a clinical impact is subject of forthcoming single cell sequencing studies. In summary, our data give guidance for practical technical considerations in a harmonized definition of MN with bi-allelic TP53 inactivation which is of utmost importance to foster the development and utilization of new targeting concepts in this dismal group of patients.

Gregor Hoermann, MD: MLL Munich Leukemia Laboratory - Current Employment